Kiren Sidhu has extensive experience in the drug development process including Phase I, (FiH) pharmacology/PK studies, bioequivalence, scintigraphy, and drug-drug interaction studies across many therapeutic indications in both healthy volunteer and patient populations.
Kiren joined Simbec-Orion in January 2018, having previously worked at PRA Health Sciences.
Within the scope of her current role, Kiren has successfully executed and managed the set-up, delivery and close out of numerous early phase studies inclusive of complex, adaptive design multi-part FiH studies. In addition, Kiren plays an active role in supporting implementation of department wide process and system improvement as well as supporting company wide initiatives.
Kiren holds an MSc in Clinical Research and a BSc (Hons) Pharmaceutical Science degree.
